PharmaPoint: Ulcerative Colitis - Japan Drug Forecast and Market Analysis to 2022 is a new market research publication announced by Reportstack. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
The research valued the UC market in Japan at $64m in 2012. By 2022, this figure is expected to rise to $173m, with a CAGR of 10.5% over the 10-year time period. Growth within this market will stem from the increasing number of prevalent cases of UC, as well as the continued uptake of the anti-TNF brand, Remicade. UC is considered a western disease in Japan, and it has been observed that with the westernization of Eastern cultures — namely, their culinary habits — UC is on the rise.
Scope
- Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Ulcerative Colitis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.
The research valued the UC market in Japan at $64m in 2012. By 2022, this figure is expected to rise to $173m, with a CAGR of 10.5% over the 10-year time period. Growth within this market will stem from the increasing number of prevalent cases of UC, as well as the continued uptake of the anti-TNF brand, Remicade. UC is considered a western disease in Japan, and it has been observed that with the westernization of Eastern cultures — namely, their culinary habits — UC is on the rise.
Scope
- Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Ulcerative Colitis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.
If you purchase this report, you can get free access to any two company profiles and their SWOT analysis from 50,000 company profiles available at Reportstack.
To view the table of contents and know more details please visit PharmaPoint: Ulcerative Colitis - Japan Drug Forecast and Market Analysis to 2022.
No comments:
Post a Comment